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Abstract
Background: A novel swine origin inﬂuenza virus (S-OIV) is continue to spread world-
wide and a global declaration of 2009 inﬂuenza pandemic was made by World Health
Organization (WHO) June 2009, this along with approaching the winter season at the
northern hemisphere, increase the interest to provide a quick, easy, affordable and
available point of care testing for S-OIV.
Objectives: To determine the performance of two rapid point-of-care (POC) tests for
inﬂuenza virus as well as direct ﬂuorescence assay for the detection of the recently
emerged a novel swine origin inﬂuenza virus (S-OIV).
Study design: A total of 143 respiratory samples which was submitted to Pathology
and Laboratory Medicine at King AbdulAziz Medical City in Riyadh, Saudi Arabia from
June 6th 2009 till June 28th 2009. All samples were tested in parallel using two
rapid assays (BD Directigen EZ Flu®) and (TruFlu, Meridian®) as well as (Imagen Flu
compare it with RT-PCR. Each test’s performed by differentA/B DFA, Oxoid®) and
team, who were blinded for other team’s result. Data gathered and we analyzed the
analytical validity of each test.
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1. Introduction
A novel swine origin inﬂuenza virus (S-OIV) was
ﬁrst identiﬁed in April 2009. The pandemic once
declared there were major moves in most of the
laboratory to ﬁnd a rapid, easy, highly sensitive and
speciﬁc diagnostic method. A novel real-time RT-
PCR for S-OIV was set up in very short time and
validated following industry-standard criteria [1,2].
Rapid diagnosis of inﬂuenza can facilitate timely
clinical management decisions and applications of
infection control precautions. Mainly because rapid
inﬂuenza antigen tests provide a result in 30min or
less, and can serve as point of care tests at emer-
gency room and triage areas. These tests are CLIA
88 regulated and are widely used for diagnosis of
inﬂuenza in central, point-of-care, and physician
ofﬁce laboratories. Several rapid antigen tests are
commercially available, some of which are able
to distinguish between inﬂuenza A and B types.
Rapid antigen tests are less sensitive in comparison
to culture and RT-PCR. In seasonal inﬂuenza with
sensitivity ranging between 50 and 80% in several
studies [1,3—5].
In this study, we evaluated the validity of two
rapid inﬂuenza A tests during the current S-OIV
H1N1 outbreak and compare it to RT-PCR results at
King Abdulaziz Medical City, In Riyadh, Saudi Arabia.
2. Materials and methods
This is a cross sectional study of the validity of
two different techniques for detection of H1N1
infection in 143 respiratory samples at KAMC dur-
ing the Inﬂuenza H1N1 pandemic, from June 6,
2009 through June 28, 2009. All 143 respiratory
samples (Nasopharyngeal swabs or Nasopharyn-
geal aspirates—–Table 1) collected from patient’s
with inﬂuenza like illness (ILI), all samples col-
lected at employee health clinic for hospital
employee and their dependant and all collected
by registered nurse (RN), NO antiviral received by
the patient prior to sample collection. Samples
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itivity of the two inﬂuenza antigen detection tests for
arison with RT-PCR, BD Directigen EZ performance was
sensitivities of 20.6% and 9.7% respectively. DFA perform
with sensitivity of 32.35%, speciﬁcity of 99.08% and PPV,
ctively.
ensitivity of the selected inﬂuenza A antigen detection
as very low, and should not be used to exclude S-OIV, DFA
especially during after hours or weekends, but negative
-PCR.
lished by Elsevier Ltd. All rights reserved.
ere tested in parallel using a real-time reverse-
ranscriptase PCR (RT-PCR) kits along with TruFlu®
apid inﬂuenza A and B, another rapid assay Directi-
en EZ (BD Medical; Sparks, Maryland ®) test and
irect ImmunoFlourecence assay (DFA) (Imagen®).
ll specimens were collected from patients with
nﬂuenza-like illness who met the World Health
rganization and CDC’s guidelines for screening and
ested within 2—4h of arrival to our laboratory, All
amples were accessioned and stored at 2 ◦C until
ested [6].
.1. PCR method
-OIV is molecularly detected by reverse-
ranscription polymerase chain reaction (RT-PCR)
ased assay. RT-PCR of S-OIV was performed at
olecular Biology Laboratory at our institute, who
re blinded to other tests results (Table 2).
Viral RNA was extracted on the QIAsymphony®SP
ystem from 400L nasopharyngeal aspirates Using
he QIAsymphony Virus/Bacteria Kits (Qiagen, Ham-
urg, Germany®). The extracted viral RNA was
luted into 60L with elution buffer. A 10L of RNA
as reverse-transcribed to cDNA using Transcriptor
irst Stand cDNA Synthesis kit (Roche Diagnostics
mbH, Mannheim, Germany®), following the man-
facturer recommendation. The resultant cDNA is
hen ampliﬁed and screened LightMix® Kit InfA M2
or detection of presence of inﬂuenza A matrix pro-
ein, all positive samples fro matrix protein then
ill be tested with speciﬁc primers and probes for
1N1 using LightMix® InfA swine H1 kit (TIB MOL-
IOL GmbH, Berlin, Germany) and following the
anufacture recommendation. PCR was performed
n a total volume of 20L in glass capillaries. The
eaction mixture used in each PCR consisted of
L of cDNA (specimen/positive control/negative
ontrol), 2L of the primers/probe mixture, 2L
f the Roche FasterStar DNA Master Hybridization
robes Kit reagent, 2.4L of MgCl2 (25mmol/L),
nd 8.6L od PCR-grade water.
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Table 1 Number and percentage of samples tested positive or negative in the inﬂuenza tests. Samples included
13 nasopharyngeal aspirates, 127 nasopharyngeal swabs and 3 throat swabs.
Result Test used
RESP DFA /Imagen TruFlu RT-PCR EZ FLU
POSITIVE Samples Number (%) 12 (8.4)
NEGATIVE Samples Number (%) 131 (91.6)
The ampliﬁcation conditions consisted of one
denaturation/activation cycle of 10min at 95 ◦C
and 50 cycles of three-temperature ampliﬁcation.
Each cycle consisted of 95 ◦C for 5 s, 62 ◦C for 5 s,
and 72 ◦C for 15 s with a single ﬂuorescent acqui-
sition step at the 62 ◦C hold. This was followed
by a melting curve analysis of 95 ◦C for 10 s, 40 ◦C
for 20 s, and a slow ramp (0.2 ◦C/s) to 85 ◦C with
continuous ﬂuorescent acquisition. The presence
of H1N1 genotype is also conﬁrmed by the melt-
ing curve analysis using the Roche lightCycler 2.0
instruments.
2.2. Rapid antigen assays
Rapid antigen assays were used according to the
manufacturer’s instructions on 100L of freshly
collected original sample from patients with ILI.
Two positive controls of known seasonal
inﬂuenza and S-OIV included in each run as well as
one known negative control.
The rapid antigen assays was performed by
Microbiology Technologists who are blinded for
other tests result.
2.3. Immuno-ﬂuorescence assay
A slide was coated by 25l of inﬂuenza A virus
reagent, then Incubated for 15min at 37 ◦C in a
moist chamber.
After the incubation period, slides washed with
Puffer Solution and placed into the PBS bath.
Then we drain off PBS and allow the slides to air
dry at room temperature (15—30 ◦C).
Finally, we added one drop of IMAGENTM mount-
ing ﬂuid to the centre of each well and place
Table 2 Test validity compare to RT-PCR.
Senstivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
TruFlu® 9.7 98.2 60 77.5
Directigen EZ® 20.6 99 87.5 80
Imagen®
Respiratory
DFA
32.35 99 90 81.2
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cover slip over the mounting ﬂuid and spec-
men ensuring that no air bubbles are trapped.
hen we examine the entire 6mm well area
ontaining the stained specimen using an ﬂuores-
ence microscope. Fluorescence should be visible
t 200×—500× magniﬁcations.
The immuno-ﬂuorescence assay was performed
y Virology Technologists who are blinded for other
ests result.
. Results
total of 143 respiratory samples were received in
he laboratory in Viral Transport Medium (VTM), all
ere tested in parallel by using two different rapid
its, DFA and RT-PCR, each team of technologists
ere blinded to other team’s results. All the data
ere entered in an ExcelTM sheets and analyzed.
Overall, all tests were able to detect S-OIV at
ariable sensitivity. For POC testing, BD Directigen
est demonstrated marginally greater sensitivity
han the TruFlu test. The sensitivity, speciﬁcity, PPV
nd NPV for TruFlu test; in comparing to RT-PCR; are
.7%, 98.2%, 60% and 77.5% respectively. While the
ensitivity, speciﬁcity, PPV and NPV for BD Directi-
en is: 20.6%, 99.08%, 87.5% and 80% respectively.
FA showed superior results than the POC tests with
ensitivity of 32.35%, speciﬁcity of 99.08%, as well
s 90% and 81.20% for positive and negative predic-
ive values respectively comparing to RT-PCR.
Viral infectivity and RNA load data for viruses at
he detection limit of the rapid test kits, suggested
hat both the BD Directigen and TruFlu tests were
ess sensitive for the detection of A novel swine ori-
in inﬂuenza virus (S-OIV) than for human seasonal
trains.
. Discussionapid Point of Care (POC) Inﬂuenza tests currently
n the market are designed to detect inﬂuenza type
, type B or both. They can distinguish inﬂuenza A
rom inﬂuenza B, but cannot distinguish S-OIV from
easonal strains of Inﬂuenza [7].
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As the S-OIV is a type A inﬂuenza virus; so if
the result is positive for inﬂuenza A, the patient
may be infected with S-OIV or with seasonal strains
of inﬂuenza A [7]. However, current data from
the US Centers for Disease Control and Prevention
(CDC) indicate that currently, 99% of the circulat-
ing inﬂuenza viruses in the United States are S-OIV
H1N1 [8]. Thus, although it is not possible to conﬁrm
S-OIV infection with an inﬂuenza rapid POC test,
a positive rapid POC test result for inﬂuenza A is
assumed to be due to infection with S-OIV H1N1
[7].
Routine testing for S-OIV using rapid POC tests is
not recommended by the CDC because the sensitiv-
ities of the currently available rapid POC tests for
the detection of S-OIV are quite poor. Various stud-
ies have shown detection rates between 11% and
70% [9,10,12,13]. This means that the rapid POC
test may fail to detect S-OIV in 30—90% of cases.
It is critical for all health care workers (HCW) to
be aware that a negative result on an inﬂuenza
rapid POC test does not rule out S-OIV infection. For
this reason, the CDC recommends that management
of patients with suspected S-OIV infection should
be based on symptoms and underlying risk factors
rather than the result of a rapid ﬂu test [8].
Physicians should also be wary of the indiscrim-
inate use of inﬂuenza rapid tests during a period
when inﬂuenza is not circulating at high levels.
This is because the speciﬁcity of these assays is
not as high as for culture or RT-PCR. The positive
predictive value of a test for an infectious disease
such as inﬂuenza depends on the speciﬁcity of the
test and on the prevalence of the disease in the
population tested [7]. If inﬂuenza prevalence is
high, the positive predictive value of a rapid test
is increased, and thus a positive test is more likely
to represent a true positive. However, during peri-
ods when inﬂuenza activity is low, such as during
most summer months, a positive result on a rapid
test is much more likely to represent a false posi-
tive. During periods of low prevalence, physicians
who require a deﬁnitive diagnosis should order tests
with high levels of speciﬁcity, such as culture or RT-
PCR, because false-positive results are signiﬁcantly
less likely [7,9—11,14—16].
5. ConclusionRapid antigen tests, DFA and the RT-PCR test all
detected the S-OIV strain, but with variable sensi-
tivity. The RT-PCR test provided the best diagnostic
option as it demonstrated superior sensitivity for
the detection of inﬂuenza A matrix protein and
[S.M. Al Johani et al.
ifferentiate between S-OIV and other inﬂuenza A
ubtyping, but it is very expensive and more labor
ntensive over other tests.
Early diagnosis of infection can assist in the rapid
reatment. However the tests are signiﬁcantly less
ensitive than PCR assays and as such, negative
esults should be veriﬁed by other laboratory tests.
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